Economists Explain Policies Restricting Pharmacy Benefits Will Lead To Higher Costs, Less Competition, And Fewer Choices For Employers In case you missed it, Joe Grogan, visiting senior fellow at the USC Schaeffer Center and former White House domestic policy adviser,
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. For Prescriptions It’s Home Sweet Home for Patients…
Approximately 9 in 10 Employers Find Pharmacy Benefit Companies Valuable When Designing their Pharmacy Benefits and Say Flexibility and Choice are Essential In case you missed it, the Coalition for Affordable Prescription Drugs (CAPD), an organization that represents a diverse
Economists Explain Policies Restricting Pharmacy Benefits Will Lead To Higher Costs, Less Competition, And Fewer Choices For Employers In case you missed it, Joe Grogan, visiting senior fellow at the USC Schaeffer Center and former White House domestic policy adviser,
Ike Brannon, former senior economist for the United States Treasury and U.S. Congress, and Anthony Lo Sasso, professor of economics at DePaul University, explain the role of pharmacy benefit companies in the prescription drug supply chain in a new Forbes
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement in response to a letter issued by the Centers for Medicare and Medicaid Services (CMS): “The Pharmaceutical Care Management Association, PCMA, representing America’s pharmacy benefit companies, believes it is
Voices from around the nation, including small business owners and concerned citizens, have sounded the alarm on proposals targeting pharmacy benefit companies in Congress, specifically how policies would lead to increased health care costs for consumers, patients, and families, and
A team of professors from Johns Hopkins University, Georgetown Law School, and Utah University College of Pharmacy published in the JAMA Health Forum a new paper, “Pharmacy Benefit Managers: History, Business Practices, Economics, and Policy,” focused on pharmacy benefit companies
Pharmacy benefit companies actively promote the use of generics and biosimilars. Take a look at the data on drug utilization: 90 percent of prescriptions dispensed are generics or biosimilars. During last week’s hearing in the House Oversight Committee, Dr. Rena
As Congress reviews legislation targeting Americans’ pharmacy benefits, Members of Congress are raising concerns about the unintended risks of significantly increasing drug costs. In case you missed it, Senator Rand Paul (R-KY) discusses recent legislation advanced by the Senate’s HELP
©2024 PCMA. All Rights Reserved.
